
    
      The primary objective of this study was to evaluate the safety of brolucizumab 6 mg delivered
      in a pre-filled syringe (PFS) in subjects with neovascular age-related macular degeneration
      (nAMD) with the primary endpoint being the incidence of ocular and non-ocular adverse events
      (AEs). There were no other objectives for this study.
    
  